About Alzheon
Alzheon is a company based in Framingham (United States) founded in 2013. Alzheon has raised $195.25 million across 12 funding rounds from investors including NIH, HHS and Ally Bridge Group. Alzheon offers products and services including valiltramiprosate and ALZ-801. Alzheon operates in a competitive market with competitors including T3D Therapeutics, Longeveron, Alchemab, Cerecin and Totus Medicines, among others.
- Headquarter Framingham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Future X Beta S.R.O.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$195.25 M (USD)
in 12 rounds
-
Latest Funding Round
$100 M (USD), Series E
Jun 12, 2024
-
Investors
NIH
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alzheon
Alzheon offers a comprehensive portfolio of products and services, including valiltramiprosate and ALZ-801.
Investigational oral drug targeting amyloid oligomers in Alzheimer's disease
Oral treatment for early Alzheimer's in APOE4 carriers
People of Alzheon
Unlock access to complete
Unlock access to complete
Funding Insights of Alzheon
Alzheon has successfully raised a total of $195.25M across 12 strategic funding rounds. The most recent funding activity was a Series E round of $100 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alzheon
Alzheon has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Alzheon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alzheon
Investment portfolio details for Alzheon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alzheon
Detailed financials for Alzheon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alzheon Comparisons
Peer comparison for Alzheon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alzheon
Alzheon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Longeveron, Alchemab, Cerecin and Totus Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
Medical foods and drugs for Alzheimer's disease are developed.
|
|
| Locked | Locked | Locked |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
Detailed competitors of Alzheon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alzheon
Complete news archive for Alzheon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alzheon
Alzheon was founded in 2013.
Alzheon is headquartered in Framingham, United States. It is registered at Framingham, Massachusetts, United States.
Alzheon is a funded company, having raised a total of $195.25M across 12 funding rounds to date.
Alzheon was founded in 2013 and is headquartered in Framingham, United States. Focus is placed on the biotechnology sector, specifically the development of oral therapeutics for Alzheimers disease. The lead candidate, ALZ-801, a prodrug of tramiprosate, is advanced as an inhibitor targeting amyloid aggregation and neurotoxicity. Clinical operations are conducted to address key pathological hallmarks of the disease.
Alzheon's top competitors include Longeveron, Alchemab and Eikonizo.
Alzheon offers valiltramiprosate and ALZ-801.
Alzheon has 4 investors. Key investors include NIH, HHS, Ally Bridge Group, and Alerce Medical Technology Partners.